30 results about "Combined antibiotics" patented technology

The invention relates to the field of biotechnology renewable energy, in particular to a method for producing endoglucanase by fermenting roughage substrates with a natural symbiotic mixed culture YakQH5, wherein the mixed culture YakQH5 is composed of anaerobic fungi (Neocallimastix frontalis) Composed of Methanobrevibacter gottschalkii, it can degrade different roughages and produce endoglucanase with high enzymatic activity, among which the activity of endoglucanase produced by degrading wheat hulls can reach 1170mU, which has achieved remarkable results Adding compound antibiotics in the fermentation process can also prevent the mixed culture YakQH5 from being polluted by bacteria during the fermentation process, and further improve the efficiency of anaerobic fermentation. The mixed culture adopted in the present invention can be preserved in vitro for survival and passage, which is convenient for popularization and provides convenience for production.

The invention relates to application of cell-penetrating peptide bound gyrA gene PNA (CPP-PNA-gyrA) combined antibiotics in preparation of a medicine for inhibiting riemerella anatipestifer. After theCPP-PNA-gyrA and antibiotics co-act on the riemerella anatipestifer, the MIC (Minimal Inhibitory Concentration) on the riemerella anatipestifer is halved, so that that the CPP-PNA-gyrA is capable ofenhancing the antibacterial effects of the antibiotics. Therefore, the CPP-PNA-gyrA can be compounded with the antibiotics to prepare the medicine for resisting the riemerella anatipestifer.

The invention relates to the field of biotechnology and renewable energy, in particular to a naturally symbiotic mixed culture YakQH5 composed of anaerobic fungi (Neocallimastix frontalis) and methanogens (Methanobrevibacter gottschalkii), which was deposited in China Microbiology on March 9, 2020 The General Microorganism Center of the Culture Preservation Management Committee, the preservation number is CGMCC No.19299, the mixed culture YakQH5 can ferment straw to produce coumaric acid esterase, and specifically discloses its fermentation method, wherein the coumarin produced by degrading sorghum straw The activity of esterase can reach 20.5mU. Adding compound antibiotics in the fermentation process can prevent the mixed culture system from being polluted by bacteria and further improve the efficiency of anaerobic fermentation, which has important industrial application value.

The invention discloses new application of a natural product hordenine and in particular relates to application of a compound hordenine in preparation of a medicine used for preventing and treating bacterial infection. The new application is mainly reflected in that hordenine can obviously inhibit synthesis of a quorum sensing-regulated signal molecule, hordenine can obviously inhibit expression of a quorum sensing-regulated virulence factor and hordenine can obviously inhibit expression of a quorum sensing-related gene. Besides, drug combination of hordenine and antibiotic netilmicin can obviously inhibit generation of a biofilm, a formed biofilm can be obviously destroyed, and the hordenine is hopeful to becoming a novel anti-infective agent for preventing and treating bacterial infection.

The invention belongs to the technical field of medical biology, and particularly relates to application of amlodipine and cephalosporin medicines to preparation of medicine-resistant combined antibiotics. After computational biology indicates that amlodipine has an inhibitory effect on beta-lactam hydrolase, medicine testing is performed by using MRSA and acinetobacter bauamnnii as models, and through combination with cephalosporin antibiotics, a relatively good bacteriostatic effect on the MRSA is achieved; novel application is provided for the amlodipine, and a novel medicinal composition is provided for positive medicine-resistant bacteria; other more effective combinations containing the amlodipine can be further developed; the conventional cephalosporin and amlodipine combinations are mature in technology, few in side effects and low in cost; and the amlodipine and cephalosporin medicines can be applied to preparation of the medicine-resistant combined antibiotics, preparation ofbeta-lactam medicine-resistant bacterium inhibiting combined antibiotics and preparation of medicines for treating respiratory infection, wound infection and infection caused by all positive bacteria.

The invention provides an application of melatonin, a medicine replacing antibiotics, to prevent Escherichia coli pathogenic infection of children with meningitis. Meningitis-type Escherichia coli was isolated and identified from the cerebrospinal fluid of muscovy ducks. This strain was used to construct a 3-week-old ICR mouse meningitis model for the first time, and the neurological symptom score, mortality difference statistics, blood-brain barrier damage degree, and meningitis-related inflammatory factors were respectively evaluated. Expression and other aspects to evaluate the successful construction of the mouse meningitis model. Taking antibiotics as a reference, the mice were treated with melatonin and four kinds of combined antibiotics, and the onset of meningitis mice was detected one week later. The results showed that both melatonin and combined antibiotics could reduce the neurological symptoms of meningitis mice. Improve the survival rate of meningitis mice, melatonin promotes the integrity of the blood-brain barrier, reduces the invasion of inflammatory cells into the central nervous system, prevents the onset of meningitis in mice through the brain-gut axis, and provides a new way to prevent neonatal meningitis. Antibiotic alternatives and treatment strategies.

The invention discloses the application of Prunella vulgaris combined with antibiotics in the preparation of anti-multidrug-resistant Staphylococcus aureus medicaments. The present invention can play a significant synergistic effect by using Prunella vulgaris in combination with antibiotics, reduces the dosage of antibiotics, reduces the minimum inhibitory concentration (MIC) of erythromycin to 1 / 2 of that used alone, and the MIC of penicillin can be reduced to 1 / 4 of the drug used alone can effectively play a combined anti-multidrug-resistant Staphylococcus aureus effect.